#1
|
|||
|
|||
Ñòàòèíû è ÑÄ 1 òèïà
Ïðîøó ñîâåòà---òðåáóåòñÿ ëè ìåäèêàìåíòîçíàÿ êîððåêöèÿ äèñëèïèäåìèè ó ïàöèåíòêè 18 ëåò ñ ÑÄ 1 òèïà (äåáþò â 3,5 ãîäà), ÎÕ-7,3; ÒÃ-N; ËÏÍÏ-4,5? Çàðàíåå ñïàñèáî!
|
#2
|
|||
|
|||
À ïî÷åìó âîçíèêëè ñîìíåíèÿ? Êîíå÷íî æå äà!
|
#3
|
||||
|
||||
Óðîâåíü ËÏÂÏ?
Êîìïåíñàöèÿ äèàáåòà (HbA1c)? Îñëîæíåíèÿ? ÒÒÃ? Ðåãóëÿðíîñòü ìåíñòðóàöèé? Êóðåíèå? ÈÌÒ? Ëèïèäåìèÿ èññëåäîâàëàñü îäíîêðàòíî? |
#4
|
|||
|
|||
ËÏÂÏ-ñåé÷àñ íå ñêàæó..HbA1c-7,2,äèàáåòè÷åñêàÿ íåôðîïàòèÿ,ñòàäèÿ ÌÀÓ,ïîëèíåéðîïàòèÿ. ÈÌÒ-25, êóðåíèå-îòðèöàåò,ìåíñòðóàöèè íå ðåãóëÿðíûå,ñî ñëîâ ïàöèåíòêè,ðàíåå òîæå îòìå÷àëîñü ïîâûøåíèå õîëåñòåðèíà...
|
#5
|
|||
|
|||
ÒÒÃ- â ðàáîòå.
|
#6
|
||||
|
||||
Äî ïîëó÷åíèÿ ðåçóëüòàòîâ ÒÒà äàâàéòå ïîäîæä¸ì ñî ñòàòèíàìè.
Èíãèáèòîðû ÀÏÔ ëèáî ñàðòàíû äåâî÷êà, êîíå÷íî, ïîëó÷àåò? Äëÿ 18-ëåòíåãî ïîäðîñòêà ãëèêèðîâàííûé 7,2% íåïëîõî, êîíå÷íî, íî õîòåëîñü áû ìåíüøå 7%. Òàì íåò õðîíè÷åñêîé ïåðåäîçèðîâêè èíñóëèíà? - äåâî÷êà ïîëíåíüêàÿ. ÀÄ íå ïîâûøàåòñÿ? Ïðè÷èíû íåðåãóëÿðíîãî ìåíñòðóàëüíîãî öèêëà óñòàíîâëåíû? |
#7
|
|||
|
|||
Îëüãà Þðüåâíà,ñïàñèáî çà îòâåò! ß â áîëüíèöå íå êàæäûé äåíü-ðåçóëüòàòû ÒÒà âûëîæó â ïÿòíèöó.Äà,äåâî÷êà ïîëíåíüêàÿ,äàâëåíèå íå ïîâûøàåòñÿ-120/80,ýíàëàïðèë-2,5ìã. Ïðè÷èíó íåðåãóëÿðíîãî ì.ö. ïîêà íå óñòàíîâèëè...
|
#8
|
|||
|
|||
ÒÒÃ-1.65
|
#9
|
||||
|
||||
ÎÊ, çäåñü âñ¸ íîðìàëüíî. Õîðîøî áû åù¸ äåâî÷êó ãèíåêîëîãàì ïîêàçàòü íà ïðåäìåò ÑÏÊß. Ìåòôîðìèí íå õîòèòå äîáàâèòü?
Ñòàòèíû ìîæíî äàòü. Íà÷íèòå ñ íåáîëüøîé äîçû, ÷åðåç ìåñÿö ïðîêîíòðîëèðóéòå ëèïèäåìèþ. |
#10
|
|||
|
|||
Ïî ïîâîäó ìåòôîðìèíà â ñîìíåíèÿõ... À ññûëîê íà ðàáîòû î ïðèìåíåíèè ìåòôîðìèíà ó ñòðàäàþùèõ ñàõàðíûì äèàáåòîì 1 òèïà, ñ èíñóëèíîðåçèñòåíòíîñòüþ íà ôîíå èçáûòî÷íîé ìàññû òåëà íåò??
|
#11
|
||||
|
||||
Ññûëîê ïî ïðèìåíåíèþ ìåòôîðìèíà ïðè äèàáåòå 1-ãî òèïà - ìîðå (çàãëÿíèòå â PubMed).
Âîò ïåðâûå, ÷òî ïîïàëèñü: Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study.Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, Parving I, Pietraszek L, Frandsen M, Rossing P, Parving HH, Vaag AA. Steno Diabetes Center, Gentofte, Denmark. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] BACKGROUND: Despite intensive insulin treatment, many patients with type-1 diabetes (T1DM) have longstanding inadequate glycaemic control. Metformin is an oral hypoglycaemic agent that improves insulin action in patients with type-2 diabetes. We investigated the effect of a one-year treatment with metformin versus placebo in patients with T1DM and persistent poor glycaemic control. METHODOLOGY/PRINCIPAL FINDINGS: One hundred patients with T1DM, preserved hypoglycaemic awareness and HaemoglobinA(1c) (HbA(1c)) > or = 8.5% during the year before enrolment entered a one-month run-in on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1 g twice daily) or placebo for 12 months (double-masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. The primary outcome measure was change in HbA(1c) after one year of treatment. At enrolment, mean (standard deviation) HbA(1c) was 9.48% (0.99) for the metformin group (n = 49) and 9.60% (0.86) for the placebo group (n = 51). Mean (95% confidence interval) baseline-adjusted differences after 12 months with metformin (n = 48) versus placebo (n = 50) were: HbA(1c), 0.13% (-0.19; 0.44), p = 0.422; Total daily insulin dose, -5.7 U/day (-8.6; -2.9), p<0.001; body weight, -1.74 kg (-3.32; -0.17), p = 0.030. Minor and overall major hypoglycaemia was not significantly different between treatments. Treatments were well tolerated. CONCLUSIONS/SIGNIFICANCE: In patients with poorly controlled T1DM, adjunct metformin therapy did not provide any improvement of glycaemic control after one year. Nevertheless, adjunct metformin treatment was associated with sustained reductions of insulin dose and body weight. Further investigations into the potential cardiovascular-protective effects of metformin therapy in patients with T1DM are warranted. TRIAL REGISTRATION: ClinicalTrials.gov NCT00118937. Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.Abdelghaffar S, Attia AM. Pediatrics, Pediatric Endocrinology and Diabetes, Cairo University. BACKGROUND: In adolescents with type 1 diabetes, insulin resistance likely plays a role in the deterioration of metabolic control. In type 1 diabetes, addition of metformin to insulin therapy, to improve insulin sensitivity, has been assessed in a few trials involving few patients or in uncontrolled studies of short duration. No systematic reviews are available up to date to summarize the evidence about metformin addition to insulin therapy in adolescents with type 1 diabetes. OBJECTIVES: To assess the effects of metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. SEARCH STRATEGY: We searched The Cochrane Library, MEDLINE and EMBASE. We also searched databases of ongoing trials, reference lists of relevant reviews, and we contacted experts, authors and manufacturers. SELECTION CRITERIA: Any randomised controlled trial (RCT) of at least three months duration of treatment comparing metformin added to insulin therapy versus insulin therapy alone in adolescents with type 1 diabetes was included. Cross-over and quasi-randomised controlled trials were excluded. DATA COLLECTION AND ANALYSIS: Two reviewers read all abstracts, assessed quality and extracted data independently. Authors were contacted for missing data. MAIN RESULTS: Only two trials (60 participants) investigating the effect of metformin added to insulin therapy for three months in adolescents with poorly controlled type 1 diabetes could be included. Meta-analysis was not possible due to the clinical and methodological heterogeneity of data. Both studies suggested that metformin treatment lowered glycosylated haemoglobin A1c (HbA1c) in adolescents with type 1 diabetes and poor metabolic control. Improvements in insulin sensitivity, body composition or serum lipids were not documented in either study, however, one study showed a decrease in insulin dosage by 10%. Adverse effects were mainly gastrointestinal in both studies and hypoglycaemia in one study. No data on health-related quality of life, all-cause mortality or morbidity are currently available. AUTHORS' CONCLUSIONS: There is some evidence suggesting improvement of metabolic control in poorly controlled adolescents with type 1 diabetes, on addition of metformin to insulin therapy. Stronger evidence is required from larger studies, carried out over longer time periods to document the long-term effects on metabolic control, health-related quality of life as well as morbidity and mortality in those patients. |